RS51055B - Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju neurodegenerativnih poremećaja - Google Patents

Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju neurodegenerativnih poremećaja

Info

Publication number
RS51055B
RS51055B YUP-674/03A YUP67403A RS51055B RS 51055 B RS51055 B RS 51055B YU P67403 A YUP67403 A YU P67403A RS 51055 B RS51055 B RS 51055B
Authority
RS
Serbia
Prior art keywords
disease
formula
group
use according
neurodegenerative disorders
Prior art date
Application number
YUP-674/03A
Other languages
English (en)
Serbian (sr)
Inventor
Carlos R. Plata-Salaman
Boyu Zhao
Roy E. Twyman
Original Assignee
Ortho-Mcneil Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical Inc. filed Critical Ortho-Mcneil Pharmaceutical Inc.
Publication of RS67403A publication Critical patent/RS67403A/sr
Publication of RS51055B publication Critical patent/RS51055B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
YUP-674/03A 2001-02-27 2002-02-21 Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju neurodegenerativnih poremećaja RS51055B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27168201P 2001-02-27 2001-02-27
PCT/US2002/005541 WO2002067925A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating neurodegenerative disorders
US10/081,764 US20020165273A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating neurodegenerative disorders

Publications (2)

Publication Number Publication Date
RS67403A RS67403A (sr) 2006-12-15
RS51055B true RS51055B (sr) 2010-10-31

Family

ID=26765943

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-674/03A RS51055B (sr) 2001-02-27 2002-02-21 Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju neurodegenerativnih poremećaja

Country Status (26)

Country Link
US (3) US20020165273A1 (enExample)
EP (1) EP1383489B1 (enExample)
JP (1) JP4276840B2 (enExample)
KR (1) KR100910928B1 (enExample)
CN (1) CN1235579C (enExample)
AR (1) AR035756A1 (enExample)
AT (1) ATE361745T1 (enExample)
BR (1) BR0207645A (enExample)
CA (1) CA2439295C (enExample)
CY (1) CY1106753T1 (enExample)
CZ (1) CZ301203B6 (enExample)
DE (1) DE60220043T2 (enExample)
DK (1) DK1383489T3 (enExample)
ES (1) ES2284845T3 (enExample)
HU (1) HUP0303264A3 (enExample)
IL (2) IL157591A0 (enExample)
MX (1) MXPA03007718A (enExample)
MY (1) MY138156A (enExample)
NO (1) NO20033798L (enExample)
NZ (1) NZ527990A (enExample)
PL (1) PL364680A1 (enExample)
PT (1) PT1383489E (enExample)
RS (1) RS51055B (enExample)
RU (1) RU2300373C2 (enExample)
TW (1) TWI312679B (enExample)
WO (1) WO2002067925A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580584C (en) * 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
ATE464044T1 (de) * 2004-09-16 2010-04-15 Janssen Pharmaceutica Nv Verwendung von 2-phenyl-1,2-ethanediol- (di)carbamaten zur behandlung von epileptogenese
KR20070085309A (ko) * 2004-10-15 2007-08-27 얀센 파마슈티카 엔.브이. 신경변성 질환 치료에 사용하는 카바메이트 화합물
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
CN101272776B (zh) * 2005-07-26 2012-10-03 詹森药业有限公司 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途
CA2665573A1 (en) * 2006-10-06 2008-04-17 Janssen Pharmaceutica N.V. Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
EP2081648A2 (en) * 2006-10-30 2009-07-29 Janssen Pharmaceutica, N.V. Carbamate compounds for use in treating depression
MX2009004798A (es) * 2006-10-31 2009-08-12 Janssen Pharmaceutica Nv Tratamiento de los trastornos generalizados del desarrollo.
ES2711619T3 (es) * 2010-07-02 2019-05-06 Bio Pharm Solutions Co Ltd Compuesto carbamato de fenilo y relajante muscular que contiene dicho compuesto
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
US20130060024A1 (en) * 2011-09-07 2013-03-07 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
WO2013100566A1 (en) 2011-12-27 2013-07-04 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same
CN109939092B (zh) * 2013-03-12 2022-03-22 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
CN110478343A (zh) 2013-03-12 2019-11-22 比皮艾思药物研发有限公司 氨基甲酸苯酯化合物和包含该化合物的用于预防或治疗神经性毒气引起的疾病的组合物
WO2017150903A1 (en) 2016-02-29 2017-09-08 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds, processes for preparing them and their uses
ES3035674T3 (en) * 2016-12-14 2025-09-08 Sk Biopharmaceuticals Co Ltd Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease
CA3112166A1 (en) * 2018-09-21 2020-03-26 Sk Biopharmaceuticals Co., Ltd. Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
CA3191072A1 (en) 2020-08-31 2022-03-03 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease
CN116234798A (zh) 2020-09-10 2023-06-06 生物药品解决方案有限公司 用于治疗或缓解精神疾病的氨基磺酸酯衍生物化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3278380A (en) * 1962-02-06 1966-10-11 Armour Pharma Methods of calming employing diphenyl hydroxy carbamate compounds
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
CN1109880A (zh) * 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
ATE369130T1 (de) * 2001-02-27 2007-08-15 Ortho Mcneil Pharm Inc Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
ES2262801T3 (es) * 2001-02-27 2006-12-01 Ortho-Mcneil Pharmaceutical, Inc. Uso de un compuesto de carbamato para la prevencion o el tratamiento de trastorno bipolar.
AU2002242296B2 (en) * 2001-02-27 2006-06-29 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating psychotic disorders

Also Published As

Publication number Publication date
CN1503667A (zh) 2004-06-09
EP1383489B1 (en) 2007-05-09
JP4276840B2 (ja) 2009-06-10
PT1383489E (pt) 2007-06-21
JP2004523555A (ja) 2004-08-05
US20020165273A1 (en) 2002-11-07
ATE361745T1 (de) 2007-06-15
ES2284845T3 (es) 2007-11-16
CA2439295A1 (en) 2002-09-06
TWI312679B (en) 2009-08-01
IL157591A (en) 2009-12-24
US20040171679A1 (en) 2004-09-02
DK1383489T3 (da) 2007-08-06
RU2300373C2 (ru) 2007-06-10
NO20033798D0 (no) 2003-08-26
BR0207645A (pt) 2004-12-28
IL157591A0 (en) 2004-03-28
MXPA03007718A (es) 2004-11-12
EP1383489A1 (en) 2004-01-28
MY138156A (en) 2009-04-30
CN1235579C (zh) 2006-01-11
KR20030076714A (ko) 2003-09-26
CZ20032313A3 (cs) 2004-08-18
RS67403A (sr) 2006-12-15
HK1060516A1 (en) 2004-08-13
KR100910928B1 (ko) 2009-08-06
DE60220043D1 (de) 2007-06-21
WO2002067925A1 (en) 2002-09-06
PL364680A1 (en) 2004-12-13
CA2439295C (en) 2010-05-25
HUP0303264A2 (hu) 2004-01-28
AR035756A1 (es) 2004-07-07
CZ301203B6 (cs) 2009-12-09
NO20033798L (no) 2003-09-26
HUP0303264A3 (en) 2012-07-30
HK1065486A1 (en) 2005-02-25
US20090005442A1 (en) 2009-01-01
NZ527990A (en) 2006-01-27
CY1106753T1 (el) 2012-05-23
DE60220043T2 (de) 2008-01-10
RU2003128982A (ru) 2005-03-10

Similar Documents

Publication Publication Date Title
RS51055B (sr) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju neurodegenerativnih poremećaja
US20100004244A1 (en) Use of cb2 receptor agonists for promoting neurogenesis
RS50676B (sr) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
RS50680B (sr) Karbamatna jedinjenja za upotrebu u sprečavanju i lečenju bipolarnih poremećaja
MY142431A (en) Oxadiazolones, processes for their preparation and their use as pharmaceuticals
US20250302773A1 (en) Compositions comprising meai and n-acylethanolamines and uses thereof
RS51056B (sr) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju psihotičkih poremećaja
MX2007004491A (es) Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos.
AU2002247203B2 (en) Carbamate compounds for use in preventing or treating neurodegenerative disordrers
HK1060516B (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
AU2002247203A1 (en) Carbamate compounds for use in preventing or treating neurodegenerative disordrers
RS50948B (sr) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju neuropatskog bola
Rejdak et al. The effect of CGP-40116 on pilocarpine evoked seizures in mice exposed to transient episode of brain ischemia
JPS5824520A (ja) 精神病治療薬
RS50946B (sr) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju neuropatskog bola u veza sa klasterskim i migrenskim glavoboljama
KR20250099634A (ko) 줄기세포로부터 분화된 유사교세포 유래 세포외 소포체의 제조방법 및 이를 유효성분으로 포함하는 신경 손상 완화 또는 치료용 조성물
Balmer Anaesthesia recovery quality and immediate postoperative analgesia after racemic ketamine or S-ketamine administration to male cats undergoing routine neutering surgery
HK1065486B (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders